Accelerating evidence gathering and approval of precision medicine therapies: the FDA takes aim at rare mutations.
作者信息
Issa Amalia M, Thorogood Adrian, Joly Yann, Knoppers Bartha M
机构信息
Personalized Medicine & Targeted Therapeutics, University of the Sciences in Philadelphia, Philadelphia, Pennsylvania, USA.
Pharmaceutical Sciences; Health Policy & Public Health, University of the Sciences in Philadelphia, Philadelphia, Pennsylvania, USA.
出版信息
Genet Med. 2019 Mar;21(3):542-544. doi: 10.1038/s41436-018-0099-0. Epub 2018 Jul 10.
Abstract
摘要
相似文献
1
Accelerating evidence gathering and approval of precision medicine therapies: the FDA takes aim at rare mutations.
Genet Med. 2019 Mar;21(3):542-544. doi: 10.1038/s41436-018-0099-0. Epub 2018 Jul 10.
2
Discussion: The FDA is Unprepared for Personalized Medicine.
Biostatistics. 2017 Jul 1;18(3):403-404. doi: 10.1093/biostatistics/kxx018.
3
Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine.
Drug Discov Today. 2020 May;25(5):813-820. doi: 10.1016/j.drudis.2020.01.023. Epub 2020 Feb 4.
4
Toward a Personalized Use of Paclitaxel.
Recent Pat Anticancer Drug Discov. 2019;14(4):296-297. doi: 10.2174/157489281404191220161014.
5
Discussion: The role, position, and function of the FDA-The past, present, and future.
Biostatistics. 2017 Jul 1;18(3):417-421. doi: 10.1093/biostatistics/kxx023.
6
The FDA Oncology Center of Excellence and precision medicine.
Exp Biol Med (Maywood). 2018 Feb;243(3):308-312. doi: 10.1177/1535370217740861. Epub 2017 Nov 6.
7
An appraisal of drug development timelines in the Era of precision oncology.
Oncotarget. 2016 Aug 16;7(33):53037-53046. doi: 10.18632/oncotarget.10588.
8
Surrogate Endpoints in Pediatric Studies Submitted to the US FDA.
Clin Pharmacol Ther. 2019 Mar;105(3):555-557. doi: 10.1002/cpt.1117. Epub 2018 Aug 9.
9
Regulations, economics hindering adoption of personalized medicine.
Am J Health Syst Pharm. 2011 Mar 1;68(5):372-4. doi: 10.2146/news110012.
10
Carvedilol and the Food and Drug Administration approval process: an introduction.
Control Clin Trials. 1999 Feb;20(1):1-15. doi: 10.1016/s0197-2456(98)00052-x.
引用本文的文献
1
Development of iPSC-based clinical trial selection platform for patients with ultrarare diseases.
Sci Adv. 2022 Apr 8;8(14):eabl4370. doi: 10.1126/sciadv.abl4370.
Zotero 插件